

Please replace the paragraph beginning on page 27, line 8 (after Table 1), with the following rewritten paragraph:

A2 For example, in rectal cancer, S-Le^a and Le^a were detected, and in colon cancer, Le^y; in lung cancer, S-Le^a, S-Le^x and Le^a; in liver cancer and pharyngitis cancer, S-Le^a, in breast cancer, S-Le^x and Le^y; in cervix uteri cancer, S-Le^a and S-Le^x; in metastasis of bone marrow lymph node, S-Le^x were detected respectively. Namely, it is found that the kinds of the modified sugar chain structures differ among the kinds of cancers.

IN THE CLAIMS:

Please cancel claims 1-30 without prejudice or disclaimer. Please add new claims 31-44 as follows:

31. (New) A method for detecting cancer, comprising the steps of:

i) a) adding to a first portion of a sample to be assayed:

A3 a first protein, said first protein being one that selectively binds to a first sugar chain structure^{or CEA}; and

an antibody against a constant region of carcinoembryonic antigens; and

(b) detecting if a complex is formed of said first protein, said antibody and carcinoembryonic antigen;

ii) a) adding to a second portion of said sample to be assayed:

a second protein, said second protein being one that selectively binds to a second sugar chain structure different from said first sugar chain structure; and

said antibody against a constant region of carcinoembryonic antigens; and

(b) detecting if a complex is formed of said second protein, said antibody, and carcinoembryonic antigen; and

iii) determining the presence of a particular cancer based on whether complexes are detected in steps (i)(b) and (ii)(b).

32. (New) The method of claim 31, further comprising:

iv) a) adding to a third portion of said sample to be assayed:

A3 a third protein, said third protein being one that selectively binds to a third sugar chain structure different from said first and second sugar chain structures; and

said antibody against a constant region of carcinoembryonic antigens; and

(b) detecting if a complex is formed of said third protein, said antibody, and carcinoembryonic antigen; and

wherein said step (iii) comprises determining the presence of a particular cancer based on whether complexes are detected in steps (i)(b), (ii)(b) and (iv)(b).

33. (New) The method of claim 32, further comprising:

v) a) adding to a fourth portion of said sample to be assayed:

a fourth protein, said fourth protein being one that selectively binds to a fourth sugar chain structure different from said first, second and third sugar chain structures; and

said antibody against a constant region of carcinoembryonic antigens; and

(b) detecting if a complex is formed of said fourth protein, said antibody, and carcinoembryonic antigen; and

wherein said step (iii) comprises determining the presence of a particular cancer based on the whether complexes are detected in steps (i)(b), (ii)(b), (iv)(b) and (v)(b).

34. (New) The method of claim 31, wherein said first protein is an Anti-Le^a antibody.

35. (New) The method of claim 34, wherein:

said second protein is an Anti-S-Le^a antibody.

36
~~37~~. (New) The method of claim 33, wherein:

said first protein is an Anti-Le^a antibody;

said second protein is an Anti-S-Le^x antibody; (D)

said third protein is an Anti-S-Le^a antibody; and

said fourth protein is an Anti-S-Le^y antibody.

37
~~38~~. (New) The method of claim ~~37~~³⁶, wherein step (iv) comprises:

determining that rectal cancer is present when there is:

a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a antibody;

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x antibody;

a detectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y
antibody.

³⁸
~~39~~ (New) The method of claim ^{✓36}~~37~~, wherein step (iv) comprises:

determining that colon cancer is present when there is:

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a
antibody;

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x
antibody;

A3 a detectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y
antibody.

³⁹
~~40~~ (New) The method of claim ^{✓36}~~37~~, wherein step (iv) comprises:

determining that lung cancer is present when there is:

a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a antibody;

a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x antibody;

a detectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y
antibody.

Rule 1.126
⁴⁰ 41. (New) The method of claim ³⁶ 37, wherein step (iv) comprises:

determining that liver cancer or pharyngitis cancer is present when there is:
a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y antibody.

A3
⁴¹ 42. (New) The method of claim ³⁶ 37, wherein step (iv) comprises:

determining that breast cancer is present when:
an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a antibody;
a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;
a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y antibody.

⁴² 43. (New) The method of claim ³⁶ 37, wherein step (iv) comprises:

determining that cervix uteri cancer is present when there is:
a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a antibody;
a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x antibody;
an undetectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y antibody.

Rule 1.126
A3
43 ~~44~~. (New) The method of claim *36* ~~37~~, wherein step (iv) comprises:

determining that metastasis of bone marrow lymph node is present when there is:

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^a antibody;

a detectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^x antibody;

an undetectable amount of complex of carcinoembryonic antigens with the Anti-Le^a antibody;

an undetectable amount of complex of carcinoembryonic antigens with the Anti-S-Le^y antibody.